Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

Presentation

Evaluation of a Human Neurovascular Model to Complement a Parallel Non-human Primate Selection for Blood–Brain Barrier Penetrant AAV Capsids

Download PDF